We evaluated TP53 somatic alterations in the first cohort, and the results showed that 241 of the 316 ESCC patients (76.3%) exhibited a total of 276 TP53 somatic mutations, which included 208 cases having only one mutation and 33 having multiple (two and three) mutations (Tables 2 and 3). This evidence concerns the gene TP53 and esophageal squamous cell carcinoma.